Kythera Biopharmaceuticals, Inc. recently shared positive interim results from its Phase IIIb, multi-center, open-label study evaluating the safety and efficacy of ATX-101, an investigational injectable drug that has demonstrated the ability to reduce unwanted submental fat, otherwise known as the stuff that puts the "double" in the double chin. First Botox now this: Kythera Biopharmaceuticals, Inc. recently shared positive interim results from its Phase IIIb, multi-center, open-label study evaluating the safety and efficacy of ATX-101, an investigational injectable drug that has demonstrated the ability to reduce unwanted submental fat, otherwise known as the stuff that puts the "double" in the double chin. The results, which were shared with attendees of the recent American Academy of Dermatology Annual Meeting in Miami Beach, found that ATX-101 is well-tolerated and may be effective in reducing SMF by both clinician and patient reported outcome measures. Read the full story here.